• Font Size

Innovation
for Life

Conquering cancer through cutting-edge
therapeutics. Learn More

Targeting the
root
of cancer

Developing novel therapeutics based on
research into cancer stem cells. Learn More

At the
forefront of
medical innovation

Award-winning R&D technology and a
leading pipeline or therapeutics targeting
cancer stem cells. Learn More

About Us

Boston Biomedical is focused on the research and development of novel cancer therapeutics, and has developed a world-leading product pipeline targeting cancer stem cells.

Product Pipeline

BBI608 is the most clinically advanced candidate in Boston Biomedical’s cancer stem cell (CSC) pathway inhibitor program. This first-in-class, orally-administered small molecule blocks CSC self-renewal and induces cell death in CSCs as well as non-stem cancer cells.

Tell me more